Axsome Therapeutics (AXSM) Misses Q4 EPS by 28c

Axsome Therapeutics (NASDAQ: AXSM) reported Q4 EPS of ($1.41), $0.28 worse than the analyst estimate of ($1.13). Revenue for the quarter came in at $24.37 million versus the consensus estimate of $21.76 million.

For earnings history and earnings-related data on Axsome Therapeutics (AXSM) click here.

You May Also Be Interested In

• EU proposes to curb Airbnb and short-term rentals amid housing shortage
• ICICI Bank (ICICIBC:IN) (IBN) PT Raised to INR2,000 at Goldman Sachs
• JPMorgan Starts Bytes Technology Group PLC (BYIT:LN) at Underweight